Pharma & Biotech - Page 17

Amgen has agreed to a $74 million settlement to resolve a class action lawsuit alleging the biotechnology giant withheld critical tax liability information from investors for far too long. The preliminary settlement

Novo Nordisk has filed a federal lawsuit against Eli Lilly and Company and Lilly USA, LLC over national advertising campaigns for two of its flagship weight-loss drugs. The suit was filed in

Novartis chief executive Vas Narasimhan has expressed confidence in the long-term commercial prospects of the company’s injectable cholesterol-lowering treatment, Leqvio. His comments come in direct response to the recent regulatory approval of

Gilead Sciences and Merck have reported positive results from two phase 3 trials backing what could become the first long-acting oral HIV treatment taken once weekly. The combination regimen pairs Merck’s islatravir

Samsung Biologics, the South Korean contract drug manufacturer, is making a major move into the fast-growing weight loss drug market with a landmark acquisition worth $1.8 billion. The company has announced plans

Cencora’s senior vice president of global supply chain, Brent Wilhelm, is drawing attention to one of pharmaceutical distribution’s most persistent blind spots. Even when a therapy is correctly stocked and staged at

Legend Biotech Corporation (NASDAQ: LEGN) saw its shares fall approximately 9 to 10% after reporting first-quarter 2026 results that disappointed investors on profitability. The decline came despite CARVYKTI net trade sales rising

Sanofi has returned to France as an Official Health Partner of the Special Olympics Unified Football World Cup, reinforcing its commitment to inclusive sport and public health awareness. The French pharmaceutical giant

Kelun has announced that its phase 3 OptiTROP-Lung06 study successfully met its primary endpoint in a significant win for its antibody-drug conjugate pipeline. The Chinese trial evaluated sac-TMT in combination with Merck’s

Veradermics has released topline results from a phase 2 study of its lead drug VDPHL01, an extended-release oral formulation of minoxidil, in women with pattern hair loss. The New Haven, Connecticut-based biotech’s